Vertex Stock Analysis

VRTX
 Stock
  

USD 288.03  13.18  4.80%   

The current rise in Vertex Pharmaceutic short term price appreciation may raise some interest from investors as it is trading at a share price of 288.03 on 2,398,500 in trading volume. The company management teams have successfully maneuvered the company at convenient times to take advantage of all market conditions in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.06. The current volatility is consistent with the ongoing market swings in July 2022 as well as with Vertex Pharmaceutic unsystematic, company-specific events.
Also, please take a look at World Market Map.
  
The Vertex Pharmaceutic stock analysis report makes it easy to digest most publicly released information about Vertex Pharmaceutic and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Vertex Stock analysis module also helps to analyze the Vertex Pharmaceutic price relationship with some important fundamental indicators such as market cap and management efficiency.

Vertex Stock Analysis Notes

About 94.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 2.54. Vertex Pharmaceutic recorded earning per share (EPS) of 8.34. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people. For more information please call Jeffrey Leiden at 617 341-6100 or visit www.vrtx.com.

Vertex Pharmaceutic Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Vertex Pharmaceutic's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Vertex Pharmaceutic or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Vertex Pharmaceutic is unlikely to experience financial distress in the next 2 years
Over 94.0% of the company outstanding shares are owned by institutional investors
Latest headline from seekingalpha.com: Vertex Stock CF Monopoly, Looking To Expand - Seeking Alpha

Vertex Pharmaceutic Upcoming and Recent Events

Earnings reports are used by Vertex Pharmaceutic to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vertex Pharmaceutic previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report7th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Vertex Largest EPS Surprises

Earnings surprises can significantly impact Vertex Pharmaceutic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2013-01-29
2012-12-31-0.08-0.09-0.0112 
2016-10-25
2016-09-300.180.16-0.0211 
2000-02-16
1999-12-310.010.030.02200 
View All Earnings Estimates

Vertex Pharmaceutic Thematic Classifications

In addition to having Vertex Pharmaceutic stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech
Biotechnology and pharmaceuticals production and services

Vertex Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Vertex Pharmaceutic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceutic backward and forwards among themselves. Vertex Pharmaceutic's institutional investor refers to the entity that pools money to purchase Vertex Pharmaceutic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Jennison Associates LlcCommon Shares1.8 M499.5 M
Sumitomo Mitsui Trust Holdings IncCommon Shares928.3 K261.6 M
Vaughan Nelson Investment Management LpCommon Shares861.6 K242.8 M
Impax Asset Management Group PlcCommon Shares860.7 K224.6 M
Victory Capital Management IncCommon Shares549.4 K154.8 M
Bnp Paribas Asset Management Holding SaCommon Shares517.1 K145.7 M
Assenagon Asset Management SaCommon Shares516 K145.4 M
Note, although Vertex Pharmaceutic's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vertex Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 69.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceutic's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceutic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Vertex Profitablity

Vertex Pharmaceutic's profitability indicators refer to fundamental financial ratios that showcase Vertex Pharmaceutic's ability to generate income relative to its revenue or operating costs. If, let's say, Vertex Pharmaceutic is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Vertex Pharmaceutic's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Vertex Pharmaceutic's profitability requires more research than a typical breakdown of Vertex Pharmaceutic's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 30.84 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 38.52 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.39.
Last ReportedProjected for 2022
Return on Investment 28.05  30.26 
Return on Average Assets 18.60  20.07 
Return on Average Equity 24.93  26.90 
Return on Invested Capital(0.0081) (0.008739) 
Return on Sales(0.0072) (0.007768) 

Management Efficiency

The entity has return on total asset (ROA) of 13.88 % which means that it generated profit of $13.88 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.65 %, meaning that it created $24.65 on every $100 dollars invested by stockholders. Vertex Pharmaceutic management efficiency ratios could be used to measure how well vertex pharmaceutic manages its routine affairs as well as how well it operates its assets and liabilities. Vertex Pharmaceutic Return on Investment is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Return on Investment of 28.05 in 2021. Return on Average Assets is likely to rise to 20.07 in 2022, whereas Return on Invested Capital is likely to drop (0.008739)  in 2022. Vertex Pharmaceutic Total Assets are fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Total Assets of 13.43 Billion in 2021. Current Assets is likely to rise to about 10.3 B in 2022, whereas Revenue to Assets are likely to drop 0.50 in 2022.
Last ReportedProjected for 2022
Book Value per Share 4.91  4.25 
Enterprise Value over EBIT-1.5 K-1.5 K
Enterprise Value over EBITDA 347.02  374.42 
Price to Book Value 12.29  11.83 
Tangible Assets Book Value per Share 9.41  8.44 
Enterprise Value16.5 B17.8 B
Tangible Asset Value2.3 B2.5 B

Technical Drivers

As of the 7th of August, Vertex Pharmaceutic has the Risk Adjusted Performance of 0.0794, coefficient of variation of 1804.81, and Semi Deviation of 2.48. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vertex Pharmaceutic, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Vertex Pharmaceutic, which can be compared to its competition. Please validate Vertex Pharmaceutic value at risk, as well as the relationship between the semi variance and kurtosis to decide if Vertex Pharmaceutic is priced more or less accurately, providing market reflects its prevalent price of 288.03 per share. Given that Vertex Pharmaceutic has jensen alpha of 0.1374, we advise you to double-check Vertex Pharmaceutic's current market performance to make sure the company can sustain itself at a future point.

Vertex Pharmaceutic Price Movement Analysis

The output start index for this execution was thirty-eight with a total number of output elements of twenty-three. The Double Exponential Moving Average indicator was developed by Patrick Mulloy. It consists of a single exponential moving average and a double exponential moving average. This indicator is more responsive to Vertex Pharmaceutic changes than the simple moving average.
.

Vertex Pharmaceutic Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vertex Pharmaceutic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vertex Pharmaceutic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vertex Pharmaceutic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Vertex Pharmaceutic Predictive Daily Indicators

Vertex Pharmaceutic intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vertex Pharmaceutic stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Vertex Pharmaceutic Forecast Models

Vertex Pharmaceutic time-series forecasting models is one of many Vertex Pharmaceutic's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vertex Pharmaceutic's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Vertex Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vertex Pharmaceutic stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vertex shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Vertex Pharmaceutic. By using and applying Vertex Stock analysis, traders can create a robust methodology for identifying Vertex entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 36.73  39.63 
EBITDA Margin 38.45  41.49 
Gross Margin 88.06  97.98 
Profit Margin 30.92  33.36 
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people.

Current Vertex Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vertex analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vertex analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
259.89Buy19Odds
Vertex Pharmaceutic current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Vertex analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Vertex stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Vertex Pharmaceutic, talking to its executives and customers, or listening to Vertex conference calls.
Vertex Analyst Advice Details

Vertex Stock Analysis Indicators

Vertex Pharmaceutic stock analysis indicators help investors evaluate how Vertex Pharmaceutic stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vertex Pharmaceutic shares will generate the highest return on investment. By understating and applying Vertex Pharmaceutic stock analysis, traders can identify Vertex Pharmaceutic position entry and exit signals to maximize returns.
Quick Ratio4.37
Fifty Two Week Low176.36
Revenue Growth21.60%
Average Daily Volume Last 10 Day1.3M
Shares Short Prior Month3.42M
Average Daily Volume In Three Month1.65M
Earnings Growth18.90%
Shares Percent Shares Out1.40%
Earnings Quarterly Growth16.70%
Gross Margins47.71%
Forward Price Earnings17.80
Short Percent Of Float1.41%
Float Shares255.13M
Fifty Two Week High296.84
Fifty Day Average276.78
Enterprise Value To Ebitda21.02
Two Hundred Day Average241.75
Enterprise Value To Revenue8.10
Also, please take a look at World Market Map. Note that the Vertex Pharmaceutic information on this page should be used as a complementary analysis to other Vertex Pharmaceutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceutic price analysis, check to measure Vertex Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceutic is operating at the current time. Most of Vertex Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceutic's price. Additionally, you may evaluate how the addition of Vertex Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Vertex Pharmaceutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceutic. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.19
Market Capitalization
70.3 B
Quarterly Revenue Growth YOY
0.22
Return On Assets
0.14
Return On Equity
0.25
The market value of Vertex Pharmaceutic is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceutic's value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceutic's market value can be influenced by many factors that don't directly affect Vertex Pharmaceutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.